CMV Connections: Paul-Bunnell Negative Mononucleosis and ‘Changelings’

Mononuclesosis is an EBV infection that can be diagnosed with the heterophil antibody test developed by Paul and Bunnell. The test is based on the agglutination of sheep erythrocytes with the blood of EBV infected patients. P-B heterophil serology is Continue reading CMV Connections: Paul-Bunnell Negative Mononucleosis and ‘Changelings’

Prospecting for New Antibiotics

The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA expedited review and more.  In addition, FDA made it quite easy to garner the label.  Continue reading Prospecting for New Antibiotics

Sulfonamides Revisited, With an Emphasis on Dapsone

The sulfonamide moiety is a remarkable structure giving rise to diverse drugs in arious therapeutic areas such as antibiotics, antidiabetics, diuretics and anti-inflammatory agents. In regards to antibiotics, sulfonamides are in common use as antifungals (P. jiroveci), antiparasitics (toxoplasmosis, cyclospora, isospora, Continue reading Sulfonamides Revisited, With an Emphasis on Dapsone

Sesquicentennial of the Clinical Thermometer

The history of the thermometer is studded with famous and familiar names. Galileo Galilei from Pisa, Santorio from Padua, and Huygens from The Hague developed temperature measuring devices, and Celsius from Uppsala, a Swede with a latinized name, Fahrenheit, from Continue reading Sesquicentennial of the Clinical Thermometer

Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

Sometimes one comes across a particularly well-written policy document which summarizes the status quo of antimicrobial resistance by connecting and synthesizing data from all kinds of sources into a coherent framework. The 2015 OECD Report on Antimicrobial Resistance in G7 Continue reading Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

ALLPHASE PHARMA – THE FIRST 100 BLOG POSTS

After the first 100 blogs, it is appropriate to reflect on reader preferences.  When I arbitrarily select a topic, it is not always clear whether what interests me also interests you. Since its start 1½ years ago, this blog has grown Continue reading ALLPHASE PHARMA – THE FIRST 100 BLOG POSTS

Avycaz Approval and Labeling Restrictions

On Feb 25, 2015 the combination of ceftazidime/avibactam (Avycaz) was approved by FDA for cUTI and cIAI infections in patients ‘who have limited or no alternative treatment options’.  As a QIDP drug, Avycaz received priority review.  Its label states that it is Continue reading Avycaz Approval and Labeling Restrictions

Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!)

It is no secret that most existing antibiotic guidelines are not getting much use these days.  The only indications pursued with any regularity are the feasible ones: ABSSSI, cUTI, and cIAI, much less CABP.  Yes, the occasional HABP/VABP trial is Continue reading Most Anti-Infective Guidelines Don’t Get No Respect (Let Alone Use!)

The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower

The recently published INSIGHT trial showed that starting HIV therapy earlier rather than later has benefit for patients 1. This should not come as a surprise considering the excellent suppressive power of current triple regimens.  The trial which enrolled 4685 Continue reading The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower

Does The Taxpayer Get Rewarded For Funding Such Studies?

Cabotegravir (S-1265744) is an integrase inhibitor similar to dolutegravir.  When formulated as a long-acting drug using crystalline nanoparticle technology it is called GSK’744 LAP.  When injected intramuscularly, ‘744 LAP it has a half-life of >1 month which makes it ideally Continue reading Does The Taxpayer Get Rewarded For Funding Such Studies?

Streptomyces – The Industrious Antibiotic Producer

Like other actinomycetes, the Streptomyces group of microbes straddles the somewhat artificial boundary between bacteria and fungi. Growth on culture plates looks ‘fungal’ and the organism produces spores and germtubes that look like mycelia.  Nonetheless these soil organisms are bacteria and of Continue reading Streptomyces – The Industrious Antibiotic Producer

Why Moxifloxacin’s Approval for Plague Is So Disturbing

PLEASE SHARE YOUR OPINION AND VOTE BELOW On May 8th, 2015 moxifloxacin/Avelox was approved for treatment of inhalational plague.[1]   We learn that the approval followed the ‘animal rule’ process, and that treatment with moxifloxacin was 100% effective in the African Green Continue reading Why Moxifloxacin’s Approval for Plague Is So Disturbing

Cattle and Pigs and Chickens, Oh Yeah!

When the Veterinary Feed Directive (VFD) Final Rule was announced earlier this month by FDA, the accompanying press release called it a ‘major step towards judicious antibiotic use’ in veterinary medicine [1]. There are several elements which look good, at least Continue reading Cattle and Pigs and Chickens, Oh Yeah!

Dosis Sola Facit Venenum – The TAB08 (aka TGN1412) Relaunch

It is a while ago (2006) when TeGenero ran its ill-fated Phase 1 study of TGN-1412, a CD28 superagonist slated for studies in diseases like rheumatoid arthritis and B-cell CLL. Unexpectedly, in this FIM study, TGN1412 generated a cytokine release Continue reading Dosis Sola Facit Venenum – The TAB08 (aka TGN1412) Relaunch

Treating GC in the Face of Dwindling Antibiotic Options – (1)

Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America.  Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg[1].   In Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1)